

Contents

Part I Gliomas

1 Astrocytic Tumors	3
Markus J. Riemenschneider and Guido Reifenberger	
1.1 Introduction	3
1.2 Epidemiological, Neuroradiological, and Clinical Features	4
1.3 Histopathology	6
1.4 Immunohistochemistry	9
1.5 Molecular Genetics	10
1.6 Molecular Diagnostics	13
1.7 Pathways to Astrocytoma and Targeted Therapies	15
1.8 Novel In Vitro and In Vivo Astrocytoma Models	18
1.9 Conclusion	20
References	21
2 Molecular Pathology of Oligodendroglial Tumors	25
Christian Hartmann and Andreas von Deimling	
2.1 Epidemiological, Neuroradiological, and Clinical Features	25
2.2 Pathology	26
2.2.1 Oligodendrogliomas WHO Grade II	27
2.2.2 Anaplastic Oligodendrogliomas WHO Grade III	27
2.2.3 Oligoastrocytomas WHO Grade II	27
2.2.4 Anaplastic Oligoastrocytomas WHO Grade III	29
2.2.5 Glioblastomas with Oligodendrogloma Component WHO Grade IV	29
2.3 Immunohistochemistry	29
2.4 Molecular Genetics	30
2.4.1 Combined Losses on Chromosome 1p and 19q in Oligodendroglial Tumors	30

2.4.2	Isolated and Combined Losses of 1p and 19q Oligodendroglial and Astrocytic Tumors.....	31
2.4.3	Mechanism for Combined Losses of 1p and 19q.....	32
2.4.4	Methods for Detection of Allelic Losses on Chromosome 1p and 19q	32
2.4.5	Tumor Suppressor Gene Identification on 1p and 19q	33
2.4.6	Candidate Genes on 1p	35
2.4.7	Candidate Genes on 19q	36
2.4.8	<i>IDH1</i> Mutations in Oligodendroglial Tumors	36
2.4.9	Progression-Associated Genetic Alterations	37
2.5	The Origin of Oligodendrogliomas	38
2.5.1	Phenotype and Genotype of Gliomas.....	38
2.5.2	Progenitor Cells of Oligodendrocytes and Oligodendroglial Tumors	38
2.6	Prognosis	38
2.6.1	Clinical and Histological/Immunohistological Prognostic Factors	39
2.6.2	Losses on 1p and 19 as a Prognostic Factor.....	39
2.6.3	MGMT as a Prognostic Factor	40
2.6.4	Other Prognostic Molecular Factors.....	40
2.7	Conclusions.....	41
	References.....	41
3	Ependymal Tumors	51
	Martin Hasselblatt	
3.1	Introduction.....	51
3.1.1	WHO Classification.....	51
3.1.2	Synonyms.....	51
3.1.3	Historical Aspects	52
3.2	Epidemiology and Clinical Features	52
3.2.1	Incidence	52
3.2.2	Age and Sex Distribution.....	52
3.2.3	Environmental Factors	53
3.2.4	Tumor Localization.....	53
3.2.5	Typical Clinical Presentation	54
3.2.6	Neuroradiological Imaging	54
3.3	Pathology.....	54
3.3.1	Macroscopic Features.....	54
3.3.2	Histological Features.....	55
3.3.3	Immunohistochemistry	56
3.4	Genetic Susceptibility and Molecular Genetics.....	57
3.4.1	Genetic Susceptibility	57
3.4.2	Molecular Genetics	57
3.4.3	Tumor Recurrence and Prognosis	59
3.4.4	Potential Molecular Targets for Therapy	60
	References.....	61

4	Pediatric Gliomas	67
	Stefan Pfister and Olaf Witt	
4.1	Introduction	67
4.2	Epidemiology and Clinical Features	68
4.3	Histopathology	71
4.4	Molecular Genetics	72
4.5	Molecular Diagnostics	74
4.6	Pathways to Pediatric Astrocytoma	75
4.7	Pathways to Pediatric Ependymoma	76
4.8	Novel Therapies for Pediatric Gliomas	76
4.9	Conclusion	78
	References	78
5	Hereditary Tumor Syndromes and Gliomas	83
	David Reuss and Andreas von Deimling	
5.1	Neurofibromatosis	83
5.1.1	Historic Aspects	83
5.1.2	Neurofibromatosis Type 1	83
5.1.3	Neurofibromatosis Type 2	87
5.2	Tuberous Sclerosis Complex	90
5.2.1	Molecular Genetics	90
5.2.2	Molecular Pathogenesis	91
5.2.3	Subependymal Giant Cell Astrocytomas	92
5.3	Li-Fraumeni and Li-Fraumeni-Like Syndrome	92
5.4	Melanoma–Astrocytoma Syndrome	93
5.5	Turcot Syndrome	93
5.6	Familial Gliomas	94
	References	94
 Part II Management of Gliomas		
6	Surgical Management of Intracranial Gliomas	105
	Matthias Simon and Johannes Schramm	
6.1	Surgical Management: Overview	105
6.2	Surgical Therapy for Gliomas: Indications and Results	106
6.2.1	Low-Grade Gliomas	106
6.2.2	Malignant Gliomas	108
6.2.3	Rare Gliomas	110

6.2.4	Cytoreductive Surgery for Gliomas in Difficult and Eloquent Locations	111
6.2.5	Recurrent Gliomas	111
6.2.6	Pediatric Gliomas	113
6.2.7	Stereotactic Biopsy and Interstitial Radiosurgery (Brachytherapy).....	114
6.3	Technical Aspects of Glioma Surgery.....	114
6.3.1	Electrophysiological Mapping and Monitoring of Eloquent Brain Areas.....	114
6.3.2	Imaging of Functional Brain Areas for Glioma Surgery.....	115
6.3.3	Image-Guided Surgery: Neuronavigation	116
6.3.4	Intraoperative Imaging	118
6.4	Perspectives	119
6.4.1	Technological Progress and Neurosurgery.....	119
6.4.2	Clinical Research and Socioeconomic Issues	119
	References.....	120
7	Radiation Therapy	125
	Stephanie E. Combs	
7.1	Low-Grade Gliomas.....	125
7.1.1	Dose Prescription: High Versus Low	126
7.1.2	Timing of Radiation Therapy: Early Versus Delayed.....	127
7.2	Anaplastic Gliomas.....	128
7.3	Glioblastoma	131
7.4	Re-irradiation	134
7.5	Conclusion	135
	References.....	135
8	Adjuvant Therapy	141
	Wolfgang Wick and Michael Weller	
8.1	Introduction.....	141
8.1.1	General Principles	141
8.1.2	Current Therapeutic Strategies.....	143
8.1.3	Alternative Modes of Application.....	146
8.1.4	Alternative Therapies	146
8.1.5	Gene Therapy	147
8.2	Astrocytic Tumors	147
8.3	Oligodendroglial Tumors	149
	References.....	150
9	Other Experimental Therapies for Glioma	155
	Manfred Westphal and Katrin Lamszus	
9.1	Introduction.....	155
9.2	Surgery	155

9.3	Chemotherapy	156
9.4	Radiation	157
9.5	New Developments	158
9.5.1	Targeted Therapies for Glioma.....	158
9.5.2	Targeting New Targets by Convection	158
9.6	Immunotherapy	159
9.7	Oncolytic Viruses	160
9.8	Gene Therapy	160
9.9	Stem Cells	161
9.10	Final Remarks	161
	References.....	161
10	Neurotoxicity of Treatment.....	165
	Pasquale Calabrese and Uwe Schlegel	
10.1	Introduction	165
10.2	Radiation	166
10.3	Radiation-Induced Neurotoxicity	166
10.4	Brain Atrophy	167
10.5	The Effect of Radiation Dosage	168
10.6	Neuropsychological Deficits Associated with Radiotherapy	168
10.7	Quality of Life After Radiotherapy	169
10.8	Other Treatment-Related Parameters Influencing Cognitive Function	170
10.9	Radiotherapy and Chemotherapy	171
10.10	Conclusions	171
10.11	Proposed Neuropsychological and Quality of Life Test Battery	172
	References	173
11	Neuroimaging	175
	R. Klingebiel and G. Böhner	
11.1	Introduction	175
11.2	MRI and CT – Technique	176
11.2.1	MRI – General Aspects	176
11.2.2	Imaging Technique	178
11.3	Indications	185
11.3.1	Differential Diagnosis of Cerebral Tumors	185
11.3.2	Peritherapeutic Imaging.....	187
11.3.3	Posttherapeutic Imaging	188
11.4	Perspectives	189
11.5	Summary	189
	Suggested Reading	190

Part III Concepts

12	Angiogenesis in Gliomas	193
	Marcia Machein and Lourdes Sánchez de Miguel	
12.1	Introduction	193
12.2	The Angiogenic Factors in Gliomas	196
12.3	Growth Factors and Their Cognate Receptors	196
12.3.1	VEGF	196
12.3.2	Angiopoietins	198
12.3.3	Other Angiogenic Growth Factors	198
12.4	Guidance Molecules	199
12.4.1	Ephrins	199
12.4.2	Delta-Like 4 Ligand-Notch	200
12.4.3	ROBO/Slit	200
12.4.4	Netrins and DCC/UNC Receptors	200
12.4.5	Semaphorins	201
12.5	Endogenous Inhibitors	201
12.5.1	Thrombospondin 1 and 2	202
12.5.2	Angiostatin	202
12.5.3	Endostatin	202
12.5.4	Pigment Epithelial-Derived Factor	202
12.5.5	PEX	203
12.6	Strategies for Therapeutic Angiogenesis Inhibition in Glioma Treatment	203
12.6.1	Inhibition of Endothelial Cell Proliferation and Adhesion Cell Molecules ...	204
12.6.2	Blocking Stimulatory Factors	205
12.6.3	Increase of Endogenous Inhibitors of Angiogenesis	206
12.6.4	Inhibition of Invasive Activity	206
12.7	Perspectives and Unanswered Questions	207
	References	207
13	Gene Regulation by Methylation	217
	Wolf C. Mueller and Andreas von Deimling	
13.1	Epigenetics	217
13.1.1	Methylation in Normal Cells and Tissues	217
13.1.2	Methylation in Cancer: General Aspects	218
13.2	Strategies of Epigenetic Studies in Gliomas	219
13.3	Methods of Epigenome Analysis	220
13.3.1	General Aspects of Methylation Analysis	220
13.3.2	Bisulfite Sequencing	221
13.3.3	Methylation-Specific PCR	221
13.3.4	Methods of Gene Identification	222
13.3.5	Genome-Wide Methylation Profiling Implementing Methylation: Sensitive Restriction Enzymes	224

13.3.6	MS-MLPA: A Novel Technique for Methylation Analysis That Does Not Require Bisulfite Modification and Can Be Reliably Applied to FFPE Tissues	224
13.3.7	Novel Platforms for Genome-Wide, High-Throughput Methylation Analyses in Cancer Samples	225
13.4	DNA: Methyltransferases and Methylation Pattern Maintenance.....	225
13.5	Epigenetically Regulated Genes of Interest in Gliomas.....	226
13.6	Diagnostic and Prognostic Value of Epigenetic Analyses: <i>MGMT</i> Promoter Methylation in Glioblastomas, Current Concepts, and Possible Future Developments	228
13.7	Current Therapeutic Strategies to Overcome TSG Silencing.....	228
13.7.1	Chromatin Remodeling Agents	228
13.7.2	Gene Replacement Therapy as a Vision for Restoring Expression of Silenced Genes.....	230
13.7.3	Artificial Transcription Factors in Gliomas	230
13.8	Conclusion and Perspective.....	231
	References.....	231
14	Brain Tumor Stem Cells	241
	Christian Nern, Daniel Sommerlad, Till Acker and Karl H. Plate	
14.1	The Concept of Cancer Stem Cells	241
14.2	Neural Stem Cells in the Adult CNS	243
14.3	Phenotypic and Functional Characterization of Neural Stem Cells.....	245
14.4	Identification and Enrichment of Brain Tumor Stem Cells.....	247
14.5	Brain Tumor Histogenesis	249
14.6	Signaling Pathways of Neural Stem Cells and Brain Tumor Cells.....	251
14.7	The (Cancer) Stem Cell Niche	252
14.8	Therapeutical Aspects	253
14.9	Outlook.....	254
	References.....	254